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Purpose: To systematically study somatic variants arising during
development in the human brain across a spectrum of neurode-
generative disorders.
Methods: In this study we developed a pipeline to identify somatic
variants from exome sequencing data in 1461 diseased and control
human brains. Eighty-eight percent of the DNA samples were
extracted from the cerebellum. Identified somatic variants were
validated by targeted amplicon sequencing and/or PyroMark® Q24.
Results: We observed somatic coding variants present in >10% of
sampled cells in at least 1% of brains. The mutational signature of
the detected variants showed a predominance of C>T variants most
consistent with arising from DNA mismatch repair, occurred
frequently in genes that are highly expressed within the central
nervous system, and with a minimum somatic mutation rate of
4.25 × 10−10 per base pair per individual.
Conclusion: These findings provide proof-of-principle that
deleterious somatic variants can affect sizeable brain regions
in at least 1% of the population, and thus have the potential to
contribute to the pathogenesis of common neurodegenerative
diseases.
Genetics in Medicine (2018) https://doi.org/10.1038/s41436-018-
0274-3
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INTRODUCTION
Pathogenic genetic variants affecting over 50 nuclear genes
contribute to the pathogenesis of late onset neurological
disorders.1 Present in every cell in the body, these genetic
variants are either inherited or arise through a de novo variant
in the gamete. In contrast, some age-related disorders such as
cancer arise through the accumulation of somatic variants
within a cell lineage during life, creating genetic heterogeneity
within a tissue or organ (somatic mosaicism). Almost half of
these variants arise decades before tumor initiation,2–4 raising
the possibility that somatic variants acquired by a similar
process during development are also present within non-
malignant human tissues. Within the nervous system, somatic
variants have been identified in rare, early onset, focal
neurological disorders such as hemimegalencephaly and
lissencephaly,5–8 demonstrating that protein-coding variants
with mosaic allelic fractions as low as 8% in the brain can
cause macroscopically overt structural neurological diseases,6
though even lower allelic fractions of around 1% may cause
milder phenotypes such as focal cortical dysplasia.9 To date,
however, the frequency of somatic variants in the human
brain, and particularly in those late onset neurological
disorders, has not been studied systematically.
MATERIAL AND METHODS
Brain samples
Ethical approval for the genetic analysis of postmortem brain
tissue was obtained from the ethical review board of each
participatingcenter. DNA was extracted from 1461 human
brains (cerebellum: n= 1281 [87.7%], cerebral cortex: n= 94
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[6.5%], basal ganglia: n= 8 [0.5%], not classified: n= 78
[5.3%]) from 1099 patients with neurodegenerative diseases
including Alzheimer disease, frontotemporal dementia or
amyotrophic lateral sclerosis (FTD-ALS), Creutzfeldt–Jakob
disease (CJD), Parkinson disease and dementia with Lewy
bodies (PD-DLB), and 362 age-matched controls within
the Medical Research Council (MRC) UK Brain Bank
Network. Controls were defined as having no antemortem
history of neurological disease, no neuropathological
features of any neurodegenerative disease, and a Braak
neurofibrillary tangle stage of ≤2 (Fig. 1a, b, Supplementary
Material Table 1 for demographics and clinical data). The
characteristics of the study group have been described
previously.10 Brain regions were sampled from available brain
regions with the maximum DNA extraction yield per
milligram of tissue.
Exome sequencing (ES) and somatic variant calling
Exome sequencing was performed on all samples as
previously described.10 Sequencing data was aligned
against the University of California–Santa Cruz (UCSC)
hg19 human reference genome using Burrows–Wheeler
Aligner (BWA).11 GATK’s Haplotype Caller from Genome
Analysis Toolkit (GATK version 3.4) was used to determine
allelic counts and genotypes across the genome.12 We
excluded the following regions within quality control: (1)
regions with the higher likelihood of misalignment and
polymerase chain reaction (PCR) artifacts in the genome;2 (2)
specific small copy-number variants (CNVs) in 1321
individuals called by array genotyping;10 and (3) sites with
read depth <30× in any sample (Fig. 1c, d, Supplementary
Material Figs. 1 and 2). This resulted in a total of 5,906,849
base pairs (bp) per individual available for subsequent
analysis.
To detect putative somatic variants, we used a modified
workflow that was initially described by Genovese et al.,2 but
this time using a pan-exome approach. Firstly, we restricted
variants to single-nucleotide variants (SNVs) and excluded
all variants with the relatively high variant allele fraction
(VAF, the ratio of variant allele: total allele) >50% or <10%
(Fig. 1c). VAFs were subsequently identified that significantly
differed from the mean VAF for heterozygous variants
(47% in our data set, binomial test P < 1 × 10−5) (Fig. 1e).
We also excluded those variants present more than once in
the cohort, and those with a minor allelic frequency (MAF)
>0.5% within the ExAC database of Human Exome Varia-
tion13 (Supplementary Material Fig. 3).
To confirm that detected putative somatic alleles also
significantly differed from the base error rate in addition to
the mean allelic frequency for a heterozygous variant, we
utilized deepSNV14,15 to compare the nucleotide counts
for each putative somatic variant against 328 random
samples within the same data set. Relative read counts were
retrieved from the BAM file of each case, and the individual
of interest was compared against the variant allele counts
for the other 328 individuals using a β-binomial distribution.
Variants with a p value <0.001 were included as putative
somatic variants. This ensured putative somatic alleles
passing both thresholds differed from both the observed
VAF of heterozygous variants, and from the local base
error rate (Fig. 1e). All putative somatic variants were
confirmed by inspection in Integrative Genomic Viewer16,17
and were annotated using ANNOVAR18 (Supplementary
Material Fig. 2).
Variant validation
Variants remaining after the above filtering strategy were then
validated by targeted amplicon sequencing to confirm a
somatic variant in cases, together with their absence from
controls (VAF<1%). Specific primers spanning putative
somatic alleles were designed using NCBIPrimerBLAST
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Ampli-
cons were generated that spanned the putative somatic
variant, and were sequenced in the sample containing the
putative somatic allele and in a control case with DNA
extracted from the same brain region. PCRs were performed
using MyTaq HS polymerase (Bioline, USA), and pooled
amplicons were sequenced using MiSeq Reagent Kit v3.0
(Illumina, CA, USA) with paired-end, 150-bp reads. FASTQ
files were analyzed using in-house bioinformatic pipelines.
Reads were aligned to the UCSC hg19 human genome
reference using BWA.11 Variant calling was performed using
GATK’s Haplotype Caller12 (minimum depth= 500×, mini-
mum supporting reads= 40, base quality ≥30 and mapping
quality ≥20), and variant to reference allelic frequencies
manually extracted from BAM files. Subsequently, all
validated variants were manually inspected and confirmed
in Integrative Genomic Viewer (IGV)16,17 (Supplementary
Material Fig. 2).
Five variants from five cases fulfilling the above criteria
were also randomly selected for validation by PyroMark® Q24
using standard protocols (Qiagen Inc). Data was analyzed
using the PyroMark Q24 software for AQ quantitation, with
relevant allelic frequencies determined from the sequencing
pyrogram. Each sample and control was run in duplicate and
the mean of the VAF determined for each allele in each
sample and control.
Occurrence of somatic variants at methylated bases
We downloaded genome bisulfite sequencing (GBS) data
from the inner cell mass (ICM) of an early developmental
human embryo.19 In total, 476,286,624 of 3,095,693,981
total bases were methylated (15.4%). We subsequently sought
to determine whether there was enrichment of somatic
mutagenesis at methylated sites by performing a binomial
test using 15.4% as the background probability against
the proportion of validated variants that occurred at
methylated bases.
Mutational spectra and signatures
Mutational spectra were derived directly from the reference
and alternative allele at each somatic variant allele. To
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Fig. 1 Detection of somatic variants in 1461 postmortem human brains. (a) Brain regions sampled within the study. (b) The proportion and number of
individuals in each cohort. (c) Unfiltered variant allele fraction (VAF) with between 10% and 35% against relative exome sequencing depth. Those that were
present before and after filtering are shown (red and blue respectively). (d) Variant detection pipeline. Section I: Exons are shown in red, with intergenic and
intronic regions as a black line. II: Regions of high genomic complexity and common structural variants (determined from population databases and previous
studies) were removed (yellow line/gray box). III: Relative sequencing depth of each exon is shown in blue above the relevant exon. Bases in which the
sequencing depth was below 30 (as depicted by the red dashed line) in an individual were removed. These regions are then shown by gray boxes on the
schematic exome and were also removed. IV: Finally, regions in which copy-number variants (gains or losses) were called from array genotyping10 were also
removed from the overall panel. An example plot of the array genotyping in which a copy-number gain has been detected is shown. Again the
corresponding region was removed from the exome depicted by a gray box on the exome panel. After these steps, remaining regions were subsequently
subjected to analysis by deepSNV and a binomial test against the mean VAF for heterozygous variants (47%). (e) Schematic representation of the putative
somatic alleles in the data set. A distribution of VAF in the whole data set is shown (pink histogram). Putative somatic alleles were those in which the
VAF was greater than base error rate (as determined from deepSNV [green box and linked inset]), and those that also differed from the binomial threshold
(<1 × 10−5) compared with an assumed VAF of 47% for heterozygosity. CJD Creutzfeldt–Jakob disease, PD-DLB Parkinson disease and dementia with Lewy
bodies
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understand the potential mechanisms of somatic mutagenesis
we compared the somatic mutation spectrum and triplet allele
(reference allele either side of the somatic allele) against
30 previously defined mutational signatures in cancer20 and
against the mutational signatures to de novo genetic variants
derived from trio studies in the population.21
Variants in the brain proteome
All gene expression data was downloaded from the Human
Protein Atlas,22 and each gene containing a somatic variant
was annotated according to the expression classification
within the brain. Genes were classed as either (1) Elevated in
brain, (2) Expressed in all, (3) Mixed expression pattern,
(4) Not detected in brain, or (5) Not detected in any tissue
as determined by the Human Protein Atlas. Binomial testing
was performed in R (v3.3) (http://CRAN.R-project.org/) to
determine whether genes containing somatic variants were
significantly different from the expression profile of all genes
across the human genome within these five categories.
Conserved genes
To determine the relative constraint for missense variation
within the germline for each gene containing a somatic
variant, we annotated each gene with the missense z-score as
determined by the Exome Aggregation Consortium (ExAC).13
Binomial testing was performed to compare the proportion of
genes within each quartile of the spectrum of missense
constraint as determined by ExAC in R.
Data availability
Clinical, pathological, and genetic data from this study have
been submitted to the European Genome-phenome Archive
(EGA, https://www.ebi.ac.uk/ega/home) under accession
number EGAS00001001599 (password available on request).
VCF files and associated and annotated metadata (clinical and
neuropathological diagnosis, age of disease onset, and age of
death) are available for download through this archive. All
requests for data should be made to the Data Access
Committee as identified through http://www.mrc.ac.uk/
research/facilities/, http://www.mrc.ac.uk/research/facilities/
brain-banks/.
RESULTS
Characteristics of variants
Exome sequencing was performed on 1461 human brain
samples from 1099 patients with neurodegenerative diseases
and 362 age-matched controls (Fig. 1a, b, Supplementary
Material Table 1). Mean sequencing depth of ES from
1461 samples was 51.9-fold (SD= 12.9), with no significant
difference between any disease or controls (one-way analysis
of variance [ANOVA] test p >0.05) (Supplementary Material
Fig. 1). Using the described filtration steps we detected
56 somatic variants in 46 brains (3.2% of 1461) (Supplemen-
tary Material Table 2). Specific short primer sequences were
able to be designed for 40 of the 56 variants using two
orthogonal methods (Supplementary Material Fig. 2), and
confirmed the presence of a somatic variant in 22 (55.0%)
of the tested alleles; a confirmation rate in keeping with
other studies of somatic variation23 (Fig. 2a, Table 1,
Supplementary Material Fig. 4). The majority of validated
variants were transitions (86.4%, n= 19) with 23.4% (n= 3)
transversions. C>T variants were by far the most common
(59.1%) (ref. 24), and 27.2% (n= 6/22) of the validated
variants occurred at bases methylated in the inner cell
mass.19 In addition, 8 of the 13 C>T pathogenic variants
(61.5%) were present at CpG sites within the genome.
None of the identified somatic variants were seen in the
heterozygote state in the 1461 brains, and all were extremely
rare in the background population.13 There was also no
difference in the frequency of somatic variants between
the different disease and control groups (Fisher exact test
p > 0.05) (Fig. 2b) indicating that, whilst mutational rates
may not be increased in patients with neurodegenerative
diseases compared with healthy aged individuals, somatic
variants at high variant allele frequencies are relatively
common in the human brain.
Mutational spectrum and signatures
We further examined the correlation between the observed
signature of base mutagenesis with the signature observed
in cancer,20 observing the strongest correlation with variants
thought to be due to mismatch repair errors occurring
during DNA replication and recombination (Pearson
product moment test r2= 0.61, p= 5.02 × 10−11) (Fig. 2c,
d). The data were also compared with mutational profile of de
novo germline variants in the population derived from
the de novo db mutation database,21 also revealing a strong
association with the mutational profile of de novo variation
(Pearson product moment test r2= 0.62, p= 2.74 × 10−11)
(Fig. 2c, d).
Pattern of gene expression and selection pressure
We subsequently determined the tissue expression pattern
of each gene in which a somatic variant was observed, and
saw that ten (58.8%) of the nonsynonymous or start-loss
variants were present in genes expressed within the brain.
These data are consistent with the notion that the somatic
variants were not selected against based on tissue expression,
and were equally distributed across the expression profile
of the human genome. This raises the possibility that
somatic variants contribute to disease pathogenesis in
several human tissues, including the brain (Fig. 2e, Supple-
mentary Material Table 3). Although speculative, VAF of
the observed somatic variants could actually reflect positive
selection of some variants, particularly if they arose in later
stages of development.
We also found no evidence that the selection pressures
seen within the germline also act on the somatic variants
we observed in the brain, with nonsynonymous somatic
variants evenly distributed across conserved and noncon-
served regions of the human genome (binomial test p=NS)
(Fig. 2f).
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Finally, we determined that 58.8% of the nonsynonymous
or start-loss variants (10/17) were predicted to be deleterious
by SIFT25 suggesting that they are highly likely to have
detrimental effects on gene expression (Table 1). When taken
together, these findings suggest that somatic variants in the
brain may not been subject to the same constraints as genetic
variation in the germline,26 rendering all regions of the brain
exome vulnerable to somatic mutagenesis, and therefore
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potentially conferring the possibility of causing a wide range
of neurodegenerative diseases.
Estimates of the mutation rate in human brains
To determine the somatic mutation rate observed within
the human brain we first assumed that the variants
occurring within the first two cell divisions of the human
zygote would give rise to VAF of 10–30%, and would
likely be present in all human tissues, having arisen
before tissue differentiation27 (Fig. 3). In this study,
after quality control (QC) and the removal of structural
variation, we analyzed 5,906,849 nucleotide bases in
each individual brain (see Methods). Across the whole
cohort (n= 1461 cases), this resulted in the analysis of
8,629,906,389 nucleotide bases, which contained 22 vali-
dated somatic variants. This equates to a mutation rate
of 2.55 × 10−9. Assuming that the detectable variants
occur at either the first or second cell divisions (corre-
sponding to an allelic fraction of 0.25 and 0.125 respec-
tively, and arising from a total of six cells; Fig. 2a, Fig. 3),
this results in a minimum somatic mutational rate
across the human exome of 4.25 × 10−10 per base pair
per individual in the first two cell divisions of the human
zygote. This is slightly lower than previously calculated
human somatic mutation rates of 2.67 × 10−9 (ref. 26),
endorsing the sensitivity of our approach. Finally, assum-
ing 3 billion bases in the full human genome, our data
suggest that ~1.3 somatic variants across the whole genome
will occur during the first two cell divisions (3 × 109
multiplied by 4.25 × 10−10). This is slightly lower than
recent estimates using genome sequencing where ~3
variants were estimated to occur per cell per division
in very early development.23 This difference could
reflect methodological differences such as the particularly
conservative nature of our validation algorithm, or be due
to a lower mutation rate across the human exome when
compared with noncoding regions.
DISCUSSION
These data are the first to quantify the degree of high-level
(VAF >10%) somatic mosaicism within the human brain,
and show that at least 1% of people possess a somatic
protein-coding variant within the central nervous system.
Given the close correlation between our observed somatic
mutation rate and previous estimates, when extrapolated
across the whole genome (of 3 billion bases), our data suggest
that each human brain may possess at least ~1.3 high-
frequency (>10% VAF) somatic variants that have arisen
during the first two embryonic cell divisions. When
considered alongside the slightly higher mutation rates
within the male germline of 1.28 × 10−8, which confers an
average of 76.9 de novo germline variants in each
individual,28 then the degree of nonanticipated inherited or
acquired genetic variation within an individual can be
extensive (~80 alleles). This has important implications in
considering the potential genetic etiology of human neuro-
logical diseases.
Whilst the number of validated somatic protein-coding
variants in our study was small at 22, we saw no evidence of
the same selective constraints seen within the germline,
which would otherwise limit the number of potentially
detrimental germline alleles acquired during development.13
Given the predominance of C>T somatic variants, the
observation that 27.2% (n= 6/22) of the validated variants
occurred at bases methylated in the inner cell mass (Table 1)
(ref. 19) implicates the deamination of methylated cytosines
as one potential mechanism, particularly given the enrich-
ment for C>T variants at CpG sites. It was also surprising
that there was a relatively strong association with the
mutational signatures seen with de novo mutagenesis within
the germline,21 suggesting that similar mechanisms of
mutagenesis may be involved in the formation of these
variants,23 albeit that they do not appear to be selected
against in the brain.
A second possibility is that the detected variants were
truly focal within the human brain, having arisen during
corticogenesis, and subsequent to tissue differentiation
during embryogenesis. For example, Poduri et al.7 detected
a focal somatic variant with a VAF of 17% within the brain
causing hemimegalencephaly that was not present in the
patient’s blood. Without additional tissue samples from
other organs we cannot exclude this possibility in the
cases we studied here. However, the lack of bias for
detectable mosaicism in any of the brain region samples
Endoderm
Mesoderm
Ectoderm
Zygote
1st mitosis
2nd mitosis
Fig. 3 Early cell division after fertilization. Schematic diagram showing
early embryonic development. An example of somatic variant (red) is
shown, with the subsequent distribution of this variant within the embryo
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(cerebellum; 17/22 (Fisher exact test versus other brain
regions p= 0.18) (Fig. 1a, Table 1), together with the lack
of focal morphological abnormalities such as those
observed by Poduri et al., point toward an early develop-
mental origin rather than a late focal origin for the variants
we report here. However, we do appreciate that we cannot
confirm this directly. These problems are likely to be
overcome by large scale, higher depth sequencing that will
detect lower levels of mosaicism. This will refine the
mutation rates and clarify the origin of variants within
individuals with neurodegenerative disorders. However,
based on the data we report here, mosaicism should also
be considered as a potential source of unexpected genetic
findings following diagnostic exome and genome sequen-
cing in neurological disorders.
It should be noted that 88% of the DNA samples studied
were extracted from the cerebellum, with no enrichment
for cerebellar or noncerebellar extraction sites within any
disease group or controls. It will be important to validate these
findings in other brain regions. This is particularly relevant
for the investigation of neurodegenerative diseases
where there is little in the way of cerebellar pathology.
Nonetheless, we have demonstrated that at least 1% of human
brain samples contain high-level somatic variants present in
at least 10% of cells. Many of these variants were extremely
rare in the germline of the population, were highly expressed
within the brain, and conferred the ability to markedly alter
protein function. Based on the observed mutational signa-
tures, we determine that they are likely to be driven by DNA
mismatch repair, and assuming an early developmental
origin, are consistent with a somatic mutation rate in the
human exome of at least 4.25 × 10−10 per base pair per
individual. Taken together these data determine the fre-
quency, nature, and likely origin of high-frequency somatic
variants in the human brain and show how they have the
potential to contribute to a range of neurological disorders.
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